Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
BCL2L1 overexpression
i
Other names:
BCL2L1, Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52, BCL2-like 1
Associations
(11)
News
Trials
C3 | Sensitive
D | Sensitive
C3 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
CD Protein Inhibitors
Immunotherapy
BCL Inhibitors
EGFR
Tyrosine Kinase Inhibitors
Immune Checkpoint Inhibitors
Threonine-Tyrosine Kinase Inhibitors
Cancel
Non Small Cell Lung Cancer
Acute Lymphocytic Leukemia
Multiple Myeloma
Gastric Cancer
Mantle Cell Lymphoma
Acute Myelogenous Leukemia
Pancreatic Cancer
Diffuse Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
osimertinib + APG-1252
C3
BCL2L1 overexpression
|
Non Small Cell Lung Cancer
|
osimertinib + APG-1252
venetoclax
C3
BCL2L1 overexpression
|
Acute Lymphocytic Leukemia
|
venetoclax
D
BCL2L1 overexpression
|
Multiple Myeloma
|
venetoclax
D
BCL2L1 overexpression
|
Mantle Cell Lymphoma
|
venetoclax
APG-1252
D
BCL2L1 overexpression
|
Gastric Cancer
|
APG-1252
venetoclax + AZD5991
D
BCL2L1 overexpression
|
Acute Myelogenous Leukemia
|
venetoclax + AZD5991
ACR-368 + ABT 263
D
BCL2L1 overexpression
|
Pancreatic Cancer
|
ACR-368 + ABT 263
venetoclax + trametinib
D
BCL2L1 overexpression
|
Multiple Myeloma
|
venetoclax + trametinib
D
BCL2L1 overexpression
|
Mantle Cell Lymphoma
|
venetoclax + trametinib
D
BCL2L1 overexpression
|
Chronic Lymphocytic Leukemia
|
venetoclax + trametinib
rituximab
C3
BCL2L1 overexpression
|
Diffuse Large B Cell Lymphoma
|
rituximab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
